Trial Profile
Evaluation of conjunctival hyperemia induced by Glanatec ophthalmic solution 0.4%
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2018
Price :
$35
*
At a glance
- Drugs Ripasudil (Primary)
- Indications Ocular hyperaemia; Open-angle glaucoma
- Focus Therapeutic Use
- Acronyms ROCKHY
- 31 Oct 2018 Status changed from recruiting to completed.
- 31 Oct 2016 Planned End Date changed from 30 Sep 2016 to 30 Sep 2017.
- 31 Oct 2016 Status changed from not yet recruiting to recruiting.